Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Development and Characterization of Yellow Fever Virus Vaccine Strain 17DD-Based Chimeric Tick-Borne Encephalitis Virus

Version 1 : Received: 15 November 2022 / Approved: 16 November 2022 / Online: 16 November 2022 (16:35:12 CET)

How to cite: Kuznetsova, N.A.; Siniavin, A.; Butenko, A.; Larichev, V.; Kozlova, A.; Usachev, E.; Nikiforova, M.; Usacheva, O.; Shchetinin, A.; Pochtovyi, A.; Shidlovskaya, E.; Odintsova, A.; Belyaeva, E.; Voskoboinikov, A.; Bessonova, A.; Vasilchenko, L.; Karganova, G.; Zlobin, V.; Logunov, D.; Gushchin, V.; Gintsburg, A. Development and Characterization of Yellow Fever Virus Vaccine Strain 17DD-Based Chimeric Tick-Borne Encephalitis Virus. Preprints 2022, 2022110315. https://doi.org/10.20944/preprints202211.0315.v1 Kuznetsova, N.A.; Siniavin, A.; Butenko, A.; Larichev, V.; Kozlova, A.; Usachev, E.; Nikiforova, M.; Usacheva, O.; Shchetinin, A.; Pochtovyi, A.; Shidlovskaya, E.; Odintsova, A.; Belyaeva, E.; Voskoboinikov, A.; Bessonova, A.; Vasilchenko, L.; Karganova, G.; Zlobin, V.; Logunov, D.; Gushchin, V.; Gintsburg, A. Development and Characterization of Yellow Fever Virus Vaccine Strain 17DD-Based Chimeric Tick-Borne Encephalitis Virus. Preprints 2022, 2022110315. https://doi.org/10.20944/preprints202211.0315.v1

Abstract

Tick-borne encephalitis virus (TBEV) is one of the most threatening pathogens which affects the human central nervous system (CNS). TBEV circulates widely in Northern Eurasia. According to ECDC the number of TBE cases increase annually. There is no specific treatment for the TBEV infection, thus vaccination is the main preventive measure. Despite the existence of several inactivated vaccines currently being licensed, the development of new TBEV vaccines remains a leading priority in countries endemic to this pathogen. Here we report new recombinant virus made by infectious subgenomic amplicon (ISA) approach using TBEV and yellow fever virus vaccine strain (YF17DD-UN) as a genetic backbone. The recombinant virus is capable of effective replication in mammalian cells and induce TBEV-neutralizing antibodies in mice. Unlike the original vector based on the yellow fever vaccine strain chimeric virus became neuroinvasive in doses of 107-106 PFU and can be used as a model of Flavivirus neuroinvasiveness, neurotropism and neurovirulence. These properties of hybrid structures are the main factors limiting their practical use as vaccines platforms.

Keywords

Tick-borne encephalitis virus; Yellow fever virus; vaccine strain; chimeric virus; infectious subgenomic amplicons; candidate vaccines

Subject

Biology and Life Sciences, Virology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.